Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI)

Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Norihiro Nishimoto, Nobuyuki Miyasaka, Kazuhiko Yamamoto, Shinichi Kawai, Tsutomu Takeuchi, Junichi Azuma, Tadamitsu Kishimoto

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX). In a multicenter, double-blind, randomized, controlled trial, 125 patients were allocated to receive either tocilizumab 8 mg/kg every 4 weeks plus MTX placebo (tocilizumab group) or tocilizumab placebo plus MTX 8 mg/week (control group) for 24 weeks. The clinical responses were measured using the American College of Rheumatology (ACR) criteria and the Disease Activity Score in 28 joints. Serum vascular endothelial growth factor (VEGF) levels were also monitored. At week 24, 25.0% in the control group and 80.3% in the tocilizumab group achieved ACR20 response. The tocilizumab group showed superior ACR response criteria over control at all time points. Additionally, serum VEGF levels were significantly decreased by tocilizumab treatment. The overall incidences of adverse events (AEs) were 72 and 92% (serious AEs: 4.7 and 6.6%; serious infections: 1.6 and 3.3%) in the control and the tocilizumab groups, respectively. All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.

Original languageEnglish
Pages (from-to)12-19
Number of pages8
JournalModern Rheumatology
Volume19
Issue number1
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Interleukin-6 Receptors
Methotrexate
Vascular Endothelial Growth Factor A
Rheumatoid Arthritis
Serum
Therapeutics
Control Groups
Placebos
tocilizumab
Rheumatology
Randomized Controlled Trials
Joints
Safety

Keywords

  • Clinical trial
  • Interleukin-6
  • Rheumatoid arthritis
  • Tocilizumab
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. / Nishimoto, Norihiro; Miyasaka, Nobuyuki; Yamamoto, Kazuhiko; Kawai, Shinichi; Takeuchi, Tsutomu; Azuma, Junichi; Kishimoto, Tadamitsu.

In: Modern Rheumatology, Vol. 19, No. 1, 2009, p. 12-19.

Research output: Contribution to journalArticle

@article{146086d0b74842bea702c315e2866a2e,
title = "Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy",
abstract = "We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX). In a multicenter, double-blind, randomized, controlled trial, 125 patients were allocated to receive either tocilizumab 8 mg/kg every 4 weeks plus MTX placebo (tocilizumab group) or tocilizumab placebo plus MTX 8 mg/week (control group) for 24 weeks. The clinical responses were measured using the American College of Rheumatology (ACR) criteria and the Disease Activity Score in 28 joints. Serum vascular endothelial growth factor (VEGF) levels were also monitored. At week 24, 25.0{\%} in the control group and 80.3{\%} in the tocilizumab group achieved ACR20 response. The tocilizumab group showed superior ACR response criteria over control at all time points. Additionally, serum VEGF levels were significantly decreased by tocilizumab treatment. The overall incidences of adverse events (AEs) were 72 and 92{\%} (serious AEs: 4.7 and 6.6{\%}; serious infections: 1.6 and 3.3{\%}) in the control and the tocilizumab groups, respectively. All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.",
keywords = "Clinical trial, Interleukin-6, Rheumatoid arthritis, Tocilizumab, Vascular endothelial growth factor",
author = "Norihiro Nishimoto and Nobuyuki Miyasaka and Kazuhiko Yamamoto and Shinichi Kawai and Tsutomu Takeuchi and Junichi Azuma and Tadamitsu Kishimoto",
year = "2009",
doi = "10.1007/s10165-008-0125-1",
language = "English",
volume = "19",
pages = "12--19",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI)

T2 - Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

AU - Nishimoto, Norihiro

AU - Miyasaka, Nobuyuki

AU - Yamamoto, Kazuhiko

AU - Kawai, Shinichi

AU - Takeuchi, Tsutomu

AU - Azuma, Junichi

AU - Kishimoto, Tadamitsu

PY - 2009

Y1 - 2009

N2 - We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX). In a multicenter, double-blind, randomized, controlled trial, 125 patients were allocated to receive either tocilizumab 8 mg/kg every 4 weeks plus MTX placebo (tocilizumab group) or tocilizumab placebo plus MTX 8 mg/week (control group) for 24 weeks. The clinical responses were measured using the American College of Rheumatology (ACR) criteria and the Disease Activity Score in 28 joints. Serum vascular endothelial growth factor (VEGF) levels were also monitored. At week 24, 25.0% in the control group and 80.3% in the tocilizumab group achieved ACR20 response. The tocilizumab group showed superior ACR response criteria over control at all time points. Additionally, serum VEGF levels were significantly decreased by tocilizumab treatment. The overall incidences of adverse events (AEs) were 72 and 92% (serious AEs: 4.7 and 6.6%; serious infections: 1.6 and 3.3%) in the control and the tocilizumab groups, respectively. All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.

AB - We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX). In a multicenter, double-blind, randomized, controlled trial, 125 patients were allocated to receive either tocilizumab 8 mg/kg every 4 weeks plus MTX placebo (tocilizumab group) or tocilizumab placebo plus MTX 8 mg/week (control group) for 24 weeks. The clinical responses were measured using the American College of Rheumatology (ACR) criteria and the Disease Activity Score in 28 joints. Serum vascular endothelial growth factor (VEGF) levels were also monitored. At week 24, 25.0% in the control group and 80.3% in the tocilizumab group achieved ACR20 response. The tocilizumab group showed superior ACR response criteria over control at all time points. Additionally, serum VEGF levels were significantly decreased by tocilizumab treatment. The overall incidences of adverse events (AEs) were 72 and 92% (serious AEs: 4.7 and 6.6%; serious infections: 1.6 and 3.3%) in the control and the tocilizumab groups, respectively. All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.

KW - Clinical trial

KW - Interleukin-6

KW - Rheumatoid arthritis

KW - Tocilizumab

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=60149105639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60149105639&partnerID=8YFLogxK

U2 - 10.1007/s10165-008-0125-1

DO - 10.1007/s10165-008-0125-1

M3 - Article

VL - 19

SP - 12

EP - 19

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -